{
    "Clinical Trial ID": "NCT00171340",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Zoledronic Acid 4 mg Upfront",
        "  Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.",
        "INTERVENTION 2: ",
        "  Zoledronic Acid 4 mg Delayed",
        "  Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Stage I-IIIa breast cancer",
        "  Postmenopausal or recently postmenopausal",
        "  Recent surgery for breast cancer",
        "  Estrogen Receptor positive and/or progesterone receptor positive hormone receptor status",
        "  No prior treatment with letrozole",
        "  Other protocol-defined inclusion criteria may apply.",
        "Exclusion Criteria:",
        "  Metastatic disease",
        "  Invasive bilateral disease",
        "  Clinical or radiological evidence of existing fracture in spine or hip",
        "  Prior treatment with IV bisphosphonates in the past 12 months",
        "  Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of baseline evaluation)",
        "  Use of Tibolone within 6 months",
        "  Prior use of parathyroid hormone for more than 1 week",
        "  Previous or concomitant malignancy",
        "  Abnormal renal function",
        "  History of disease effecting bone metabolism",
        "  Other protocol-defined exclusion criteria may apply."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.",
        "  Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).",
        "  Time frame: Baseline, 12 months",
        "Results 1: ",
        "  Arm/Group Title: Zoledronic Acid 4 mg Upfront",
        "  Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.",
        "  Overall Number of Participants Analyzed: 423",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Percentage change in BMD  2.208         (3.4194)",
        "Results 2: ",
        "  Arm/Group Title: Zoledronic Acid 4 mg Delayed",
        "  Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.",
        "  Overall Number of Participants Analyzed: 418",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Percentage change in BMD  -3.617         (4.2151)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 133/525 (25.33%)",
        "  Anaemia 1/525 (0.19%)",
        "  Febrile neutropenia 1/525 (0.19%)",
        "  Acute myocardial infarction 2/525 (0.38%)",
        "  Angina pectoris 3/525 (0.57%)",
        "  Angina unstable 1/525 (0.19%)",
        "  Aortic valve incompetence 1/525 (0.19%)",
        "  Arrhythmia 0/525 (0.00%)",
        "  Atrial fibrillation 1/525 (0.19%)",
        "  Atrioventricular block complete 0/525 (0.00%)",
        "  Cardiac arrest 0/525 (0.00%)",
        "Adverse Events 2:",
        "  Total: 124/535 (23.18%)",
        "  Anaemia 1/535 (0.19%)",
        "  Febrile neutropenia 0/535 (0.00%)",
        "  Acute myocardial infarction 0/535 (0.00%)",
        "  Angina pectoris 2/535 (0.37%)",
        "  Angina unstable 0/535 (0.00%)",
        "  Aortic valve incompetence 1/535 (0.19%)",
        "  Arrhythmia 1/535 (0.19%)",
        "  Atrial fibrillation 4/535 (0.75%)",
        "  Atrioventricular block complete 1/535 (0.19%)",
        "  Cardiac arrest 2/535 (0.37%)"
    ]
}